Yili Chuanning Biotechnology (301301) Revenue Breakdown - Main Composition

8.90
0.000.00%

Market Closed May 29 15:00 CST

19.85BMarket Cap33.58P/E (TTM)

Yili Chuanning Biotechnology (301301) Revenue Breakdown Overview

By Product

Currency:CNY

2025/FY

Stock NameRevenueRatio

Pharmaceutical intermediates4.15B89.92%

Other business389.55M8.44%

Other products75.71M1.64%

By Industry

Currency:CNY

2025/FY

Stock NameRevenueRatio

Pharmaceutical manufacturing industry4.23B91.56%

Other business389.55M8.44%

By Country/Region

Currency:CNY

2025/FY

Stock NameRevenueRatio

East China1.87B40.53%

North China884.49M19.16%

Exit624.44M13.53%

South China490.59M10.63%

Northwest405.23M8.78%

Central China230.71M5.00%

Southwest86.77M1.88%

Northeast China23.3M0.50%

View all

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

On May 29, Eastern Time, Trump held a two-hour meeting in the White House Situation Room but has not yet reached a final decision on negotia Show More

Futubull Options Sir

May 26 18:03

Options Sir on Macro | Big Week Ahead! US-Iran Deal May Materialize + PCE Data Looms—How to Navigate Markets Next?

牛牛課堂

Mar 4 17:09

Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.